Calcium (Ca) balance is the net of Ca intake and output from the body over a period of time. The concept of Ca balance does not consider the redistribution of Ca that often occurs in patients with chronic kidney disease (CKD), especially those who are on dialysis, which is often in the form of soft tissue and/or vascular calcification. In this article, we consider movement of Ca with respect to the extracellular fluid (ECF) and develop a mathematical formulation for Ca homeostasis with respect to the ECF that includes input and output from the diet, the bone, the kidney, and dialysis. We consider calcium homeostasis in healthy individuals and in patients with excess parathyroid hormone, excess 1,25-dihydroxyvitamin D 3 , and metabolic acidosis; patients who have CKD and are not on dialysis; and, finally, patients who have CKD and are on dialysis. On the basis of a number of assumptions, dialysis patients with a daily intake of >37.5 mmol of elemental Ca (1.5 g) have movement of Ca into the ECF even without supplemental activated vitamin D. Addition of activated vitamin D, which increases intestinal Ca absorption and can increase resorption of Ca from bone, leads to the movement of Ca into the ECF at virtually all levels of intake; however, there are numerous unanswered questions regarding Ca homeostasis in patients with CKD, including how much of the Ca, administered as a phosphate binder, is absorbed and what is the fate of this absorbed Ca. Until these pressing questions are answered with well-designed experiments, we do not know whether we are doing more harm than good for our dialysis patients by administering additional Ca as a phosphate binder, especially when they also receive activated vitamin D.
C alcium (Ca) balance is the net of Ca intake and output from the body over a period of time. Although the concept of Ca balance is instructive, it does not consider the redistribution of Ca that often occurs in patients with chronic kidney disease (CKD), especially those who are on dialysis. This redistribution of Ca, often in the form of soft tissue and/or vascular calcification, suggests that consideration of overall balance is insufficient for our patients with CKD. Patients with extraosseous calcification may be in positive, neutral, or negative total Ca balance. In dialysis patients, total body Ca is often maldistributed. Thus, in this article, we consider movement of Ca with respect to the extracellular fluid (ECF).
The ECF, especially the plasma water, provides a conduit to connect the gastrointestinal (GI) tract, kidney, and bone. The daily fluxes of Ca between these organs are often far greater than the total Ca content of the ECF. Although there is continual input of Ca into and out of the ECF, net Ca movement relative to the ECF in adults should ideally be 0. If there is net Ca input into the ECF from intestinal Ca absorption or bone resorption or, in the case of patients who are on dialysis, an influx of Ca from the dialysis procedure, then the Ca input into the ECF must be deposited "somewhere," because the ECF Ca concentration must be held relatively constant to maintain optimal cellular function. In patients with CKD, that "somewhere" is often at extraosseous sites such as soft tissue or vessels (1) (2) (3) . The blood Ca concentration is not informative as to whether Ca is moving into or out of the ECF. The level of blood Ca, specifically the concentration of the biologically active ionized Ca, is set by a variety of hormones and other factors, such as the amount of unmineralized collagen, to provide optimal cellular function and is not a "gauge" of how much Ca is in the body or moving into or out of the ECF. Continual movement of Ca into the ECF from the intestine and/or bone will increase blood Ca concentration only when it exceeds the rate of Ca deposition at other ECF sites (e.g., soft tissue).
Determinants of Extracellular Ca Content
At a constant ECF volume, a change in the ECF Ca content reflects a change in the difference between the continual input and output of Ca from the ECF (equation 1), ⌬ECF Ca ϭ ECF input Ca Ϫ ECF output Ca (1)
where ⌬ECF Ca is change in the ECF Ca content (mass/unit time), ECF input Ca is gain of Ca into the ECF (mass/unit time), and ECF output Ca is loss of Ca from the ECF (mass/unit time) (4) . ⌬ECF Ca will normally be 0, because the input and output of Ca over a short period of time (seconds to minutes) are identical. ⌬ECF Ca will become positive when the input of Ca to the ECF exceeds the output of Ca from the ECF and negative when output exceeds the input. A change in ⌬ECF Ca will alter the Ca content in the ECF according to the following relationship:
͑ECF Ca ͒ new ϭ ͑⌬ECF Ca ϫ time͒ ϩ ͑ECF Ca ͒ old (2) where (ECF Ca ) new is new ECF volume Ca content (mass) at the end of the time period (time), and (ECF Ca ) old is ECF Ca content at the beginning of the time period.
In this analysis, we are most concerned with ECF Ca content. It is understood that the ECF consists not only of the plasma water but also of the interstitial, transcellular, bone, and connective tissue fluid. The equilibrium of Ca between the many ECF compartments, especially the bone fluid, is not well understood. Although the bone mineral, strictly speaking, is part of the ECF, for the purposes of this analysis, it is treated as a separate compartment because only approximately 1% of the Ca contained within the bone mineral is readily accessible to the ECF (5). In addition, Ca deposition in bone has far different consequences than Ca deposition in soft tissues such as the vasculature.
Calcium Input to the ECF
In people with normal renal function, net input of Ca into the ECF can come only from bone mineral resorption and intestinal Ca absorption (equation 3; Figure 1 ) because the kidney can reabsorb only filtered Ca.
ECF input
where Br Ca is Ca released during bone resorption (mass/unit time), D Ca is dietary Ca supply (mass/unit time), and ␣ Ca is fraction of intestinal Ca absorbed (4) . ␣ Ca is defined as follows:
␣ Ca ϭ ͑dietary Ca intake Ϫ fecal Ca excretion͒/dietary Ca intake (4)
Ca may be absorbed in all segments of the small intestine through paracellular diffusion and active transport (6 -8 For this analysis, it is not necessary to subdivide the reabsorption of secreted Ca from the absorption of dietary Ca. Note that ␣ Ca reflects overall net Ca absorption, which takes into account reabsorption of any Ca secreted into the intestine. Thus, ␣ Ca may be negative, for example, during consumption of an extremely low-Ca diet, when there is little intake of Ca and some of the secreted intestinal Ca is lost in the feces.
In patients who are on dialysis, Ca can enter the ECF through the dialysis procedure when the dialysis bath Ca concentration exceeds that of the blood ionized Ca (equation 5):
where Dial Ca In is Ca input to the ECF from the dialysis procedure.
Calcium Output from the ECF
In patients with normal renal function, output of Ca from the ECF can occur through any combination of bone formation, renal Ca excretion, or sweat (equation 6):
where Bf Ca is Ca being deposited on the bone (mass/unit time); UF Ca is ultrafilterable Ca; fr Ca is overall renal tubule fractional reabsorption of Ca; and Sweat Ca is the calcium lost in sweat, which includes other minor loses such as hair, desquamated skin, finger nails, etc. (4). We have excluded from this equation the large Ca loss in the milk of lactating women, although this analysis could be extended to lactating women by simply adding a term for this loss. Pregnant women are included because there is no distinction between bone formation in the mother or the fetus.
Patients who are on dialysis can also lose Ca from the ECF into the dialysate. Patients who are on dialysis may have residual renal function with the loss of some urinary Ca:
where Dial Ca Out is Ca lost from the ECF during the dialysis procedure. Thus,
JB Ca is defined as the net efflux of Ca from the bone mineral:
and JB Ca consists of the combination of a net cellular Ca flux and a net physicochemical Ca flux, both in units of mass/unit time. A positive JB Ca indicates an efflux of Ca from bone into the ECF, whereas a negative JB Ca indicates an influx of Ca from the ECF into bone. The vast majority of body Ca is contained within bone mineral (10,11). JDialysis Ca is defined as the net flux of Ca from the dialysis procedure:
A positive JDialysis Ca indicates an efflux of Ca from dialysate into the ECF, and a negative JDialysis Ca reflects an influx of Ca from the ECF into the dialysate. Finally, over a period of time, Regulation of [Ca ion ] at the level of the bone is also an attractive hypothesis. Bone formation and resorption are regulated by alterations in the physicochemical driving forces for mineralization and demineralization and by alterations in osteoclastic and osteoblastic activity (13). The ECF is markedly supersaturated with respect to apatite, which is the most abundant phase of the bone mineral (20,21). There seems to be a barrier to the free diffusion of Ca from the ECF into the mineral, which would prevent circulating Ca from being readily incorporated into apatite (22). The nature of this barrier is not clear but seems to be an early phase of the mineral, perhaps Ca phosphate (CaHPO 4 ) or Ca carbonate (CaCO 3 ) or a cellularorganic layer. Cultured bone seems to be in passive physicochemical equilibrium with CaCO 3 in the bone mineral (21). Lowering the driving force of the medium for crystallization with respect to CaCO 3 induces loss of bone mineral, whereas increasing the driving forces results in an increase in the mineral. If experimental results with cultured bone can be applied to humans, then this would suggest that a lowered [Ca ion ] would decrease the driving force for mineralization with respect to an early, relatively unstable phase of the mineral and result in an efflux of Ca from bone to increase ⌬ECF Ca . Similarly, an increase in [Ca ion ] would result in movement of Ca from the ECF onto an early phase of the resident mineral. Thus, changes in the [Ca ion ] are lessened or "buffered" by the bone mineral. Regulation of [Ca ion ] can also occur through hormonal alterations in cell-mediated bone resorption and formation, as described already, although these processes would probably not be operative during very short periods of time (minutes).
Sites of Regulation of Calcium Concentration
There 
Specific Examples
Ideally, in healthy, nonpregnant adults without osteoporosis, ⌬ECF Ca will remain at 0 for long periods of time. If it increases, then the additional Ca will migrate out of the ECF and into bone, soft tissues and/or vessels. Although in patients with CKD phosphate seems to be a prime regulator driving the transition of vascular smooth muscle cells to become collagensecreting osteoblasts (23,24), soft tissue and vascular calcification cannot occur unless Ca is deposited with phosphate on the collagen matrix. If ⌬ECF Ca becomes negative for any period of time, then Ca must leave the bone mineral, which is the only substantial repository of Ca in the body (10,11). Let us examine each of these parameters in normal individuals, then in patients with excess PTH and those with acidosis, two principal metabolic disorders that occur in patients with CKD. We also address the addition of 1,25(OH) 2 D 3 and, finally, discuss patients who have complete renal failure and receive dialysis.
Normal Individuals
A 70-kg man has an ECF volume of approximately 14 L with an ECF[Ca total ] of approximately 2.5 mM, leading to a total ECF Ca (excluding the bone mineral) of approximately 35 mmol, which is approximately 0.1% of total body Ca (11,25-27). The vast majority of total body Ca is contained within the mineral phases of bone (10,11). Although there clearly are differences in total skeletal Ca content on the basis of genetic background and gender (28) , through cadaveric chemical analysis and neutron activation analysis, it is estimated that bone contains approximately 31,350 mmol of the total body Ca content of approximately 31,500 mmol. Thus, Ͼ99.5% of total body Ca resides within the bone (11,25-27). Bone mass peaks at approximately age 25, and loss of trabecular mineral begins at approximately age 35 in women (29) . Much of the Ca contained within the bone mineral is inaccessible to the ECF, at least in the short term, but approximately 1% of total body Ca resides within a freely exchangeable pool between the bone and the ECF (5).
The normal American diet contains approximately 20 mmol of Ca, approximately 16 mmol of which is excreted in the feces, indicating that the fraction of Ca absorbed, ␣ Ca , equals approximately 0.20 (14, 25, 30) . Intestinal absorption of Ca is increased during periods of rapid growth and during pregnancy and lactation.
Excretion of Ca by the kidney represents the difference between the renal filtered load of Ca and the tubular reabsorption 015 (15,30 -32 ). U Ca varies directly but not linearly with Ca intake, as well as with the intake of sodium and protein and inversely with phosphorus intake (15). The mass of elemental Ca filtered by the normal kidney each day is far greater than the total mass of Ca circulating in the ECF. Loss of Ca from sweat has been estimated at 1.6 mmol/d but may increase substantially during exercise (33) .
During the course of a day in the normal adult who ingests a diet adequate in Ca, there is no appreciable net bone formation or resorption (i.e., JB Ca ϭ 0). . UF Ca will increase to such an extent that the elevated UF Ca exceeds the increase in fr Ca , leading to an absolute increase in U Ca (38, 39) . In many patients, the excess PTH stimulates an increase in 1,25(OH) 2 D 3 (40) , resulting in an increase in ␣ Ca and the product D Ca ϫ ␣ Ca (41, 42 (43) (44) (45) (46) (47) .
The chronic excess PTH that occurs in CKD (16,17) also leads to predictable responses. The excess PTH increases fr Ca , and, as the GFR falls, the loss of filtration makes the term [GFR ϫ UF Ca ϫ (1 Ϫ fr Ca )] approach 0 (17). Indeed, in stage 2 CKD, U Ca is already significantly lower compared with stage 1 CKD, and in stages 3, 4, and 5 CKD, U Ca is Ͻ2.5 mmol/24 h (17). The PTH-induced increase in bone turnover favors osteoclastic bone resorption (i.e., Br Ca Ͼ Bf Ca ), leading to a positive JB Ca . Because of the loss of renal mass and the increase in phosphorus and FGF-23, there is a marked reduction in production of 1,25(OH) 2 D 3 (48, 49) , and ␣ Ca therefore falls. D Ca ϫ ␣ Ca will decrease unless patients are given activated vitamin D that will increase ␣ Ca or Ca-containing phosphate binders that will increase D Ca . With either activated vitamin D administration or use of Ca-containing phosphate binders or even more with the combination, (D Ca ϫ ␣ Ca ) will increase. The actual amount of this increase cannot be determined without the proper studies, which have yet to be performed.
Excess 1,25(OH) 2 D 3
The administration of excess 1,25(OH) 2 D 3 will have the primary effect of increasing ␣ Ca , leading to an increase in the product D Ca ϫ ␣ Ca (50) . ⌬ECF Ca will be positive, resulting in an increase in [ECF Ca ] new and UF Ca and thus, in the product GFR ϫ UF Ca . [Ca ion ] will also increase, causing a fall in PTH (37) and thus fr Ca , and a rise in (1 Ϫ fr Ca ) and in GFR ϫ UF Ca ϫ (1 Ϫ fr Ca ). There is no consistent evidence that 1,25(OH) 2 D 3 itself will alter fr Ca independent of PTH. U Ca will increase markedly under the influence of an increased UF Ca and decreased fr Ca (39) . In vitro 1,25(OH) 2 
Metabolic Acidosis
A lowered systemic pH will increase the displacement of albumin-bound Ca, increasing [Ca ion ] and UF Ca (27, 56) . ⌬ECF Ca is not altered, because acidosis displaces only Ca bound to albumin (27,56) but does not increase the [Ca total ] (57). Acidosis will also decrease fr Ca through a direct effect of lowered bicarbonate on renal tubular Ca reabsorption (58, 59) . Decreased pH independent of decreased HCO 3 Ϫ will not decrease fr Ca (60) . The net result of an increased UF Ca and decreased fr Ca , despite some fall in GFR (58) , is a marked increase in U Ca (15,61). The effect of acidosis on serum levels of PTH and 1,25(OH) 2 D 3 have been studied in some detail in humans (62, 63) and animals (43, 57 despite the calciuria and negative Ca balance; however, during acidosis, the infusion of PTH will increase serum 1,25(OH) 2 D 3 (67) . ␣ Ca does not seem to change appreciably in humans during acidosis (58, 62, 68) .
During metabolic acidosis, the increase in U Ca seems to come from bone (58, 69, 70) . Indeed, bone mineral, especially carbonate, has been reported to decrease during metabolic acidosis (66, 71, 72) , and provision of bicarbonate increases bone mineral (73, 74) . In vitro metabolic acidosis increases Ca efflux from bone both by promoting physicochemical mineral dissolution within hours (13), especially of CaCO 3 (21), and by enhancing osteoclastic bone resorption over longer periods (13).
CKD in Patients Who Are not on Dialysis
Elevated levels of PTH are consistently found in patients with renal failure, and the greater the impairment of renal function, the higher the level of PTH (16, 17, (75) (76) (77) . Secretion of PTH is increased principally as a result of the decline in [Ca ion ] (78); however, the reduction in 1,25(OH) 2 D 3 and the increase in phosphate itself (as a result of the reduction in phosphate excretion coupled with continued intestinal absorption) both will increase PTH secretion (79, 80) . The factors that are responsible for the low [Ca ion ] are multiple, and the importance of each remains controversial. Phosphate retention, decreased serum 1,25(OH) 2 D 3 production with the consequent reduction of ␣ Ca , alteration in the set point for PTH secretion, skeletal resistance to PTH, and impaired degradation of PTH all may contribute to the increase in serum levels of PTH. The excess PTH and the acidemia produced by failure to excrete endogenous acids will promote bone mineral resorption in vitro (81) and potentially in patients with CKD (82) .
Phosphate retention will increase PTH levels in humans (83) and experimental animals (84) with no impairment in renal function. In animals with renal failure and in patients with CKD, elevated PTH levels are a function of the degree of hyperphosphatemia (85) (86) (87) (88) . Hyperphosphatemia itself will lead to an increase in PTH secretion in intact cultured parathyroid glands (89) . [Ca ion ] may fall because increased phosphate will decrease the physicochemical driving forces for bone mineral dissolution (21) and favor ectopic precipitation of Ca phosphate complexes (90) . In addition, phosphate retention will directly decrease serum 1,25(OH) 2 (99, (102) (103) (104) (105) . In addition, during renal failure, there is decreased binding of 1,25(OH) 2 D 3 to the parathyroid cells (106) . Thus, during renal failure, the combination of lower levels of 1,25(OH) 2 D 3 and decreased binding of the available 1,25(OH) 2 D 3 to the parathyroid cells results in a marked increase in secretion of PTH at all levels of [Ca ion ]. This so-called "altered set point" for PTH secretion can be reversed by the administration of intravenous 1,25(OH) 2 D 3 (107, 108) or vitamin D analogues (109) . PTH is degraded principally in the liver and kidney into carboxy-terminal fragments, which are catabolized by the kidney (110 -112) . With renal failure, there is accumulation of PTH fragments in the serum, some of which are biologically active (113, 114) . Despite evidence for the skeletal resistance to the actions of PTH on bone during renal failure, excess PTH promotes resorption of bone mineral in uremia, leading to increased Br Ca and JB Ca (88, (115) (116) (117) .
Thus, in renal failure, ⌬ECF Ca is negative as a result of a decrease in the product D Ca ϫ ␣ Ca , despite a decrease in the U Ca as a result of a lowered GFR and a PTH-induced increase in Br Ca . When 1,25(OH) 2 D 3 is administered, especially with additional Ca from Ca-based phosphate binders, there is an increase in ␣ Ca , often leading to a positive ⌬ECF Ca and frank hypercalcemia (107) (108) (109) .
CKD in Patients Who Are on Dialysis
The dialysis procedure itself can lead to a net influx of Ca to the ECF, Dial Ca In, or a net efflux of Ca from the ECF, Dial Ca Out. Ca flux is a function of diffusion and convection. With respect to diffusion, a higher dialysate Ca will lead to Ca influx directly into the ECF, whereas a lower dialysate Ca results in Ca efflux from the ECF. With a 0.75-mM Ca bath, there is a reduction of plasma Ca during the dialysis procedure, suggesting Dial Ca Out, and with a 1.75-mM Ca bath, there is an increase in plasma Ca, suggesting Dial Ca In (118, 119) 
A Model of ⌬ECF Ca during a 1-Wk Period
To model ⌬ECF Ca for a patient who is on dialysis, we must make a number of assumptions because experimental data are not yet available. Each assumption is backed by available data in the literature; however, there is a paucity of data on intestinal Ca absorption and secretion in dialysis patients. There are almost no data on movement of Ca between the intestine, bone, and kidney in patients who are on dialysis. These data are critical because movement of a small amount of Ca from bone to the soft tissue-with no change in overall Ca balance-can result in substantial vascular and soft tissue calcification. The assumptions are as follows: with a constant correction for secretion of Ca into the GI tract and sweat. Changing any of these assumptions will obviously have important effects on the outcome. For example, any appreciable U Ca will lessen ⌬ECF Ca , and any appreciable Br Ca from excess PTH or administered activated vitamin D will increase ⌬ECF Ca .
In Figure 2 , ⌬ECF Ca , the change in the ECF Ca content (mmol/wk), is plotted as a function of Ca intake (mmol/d), calculated on the basis of the aforementioned assumptions. With no activated vitamin D, an intake of 25 mmol (1 g) of elemental Ca results in a negative ⌬ECF Ca during the week, whereas an intake of 50 mmol results in a positive ⌬ECF Ca . Addition of activated vitamin D increases ⌬ECF Ca at all levels of Ca intake. These results are consistent with those of Hsu et al. (127) , except that they did not consider Ca secretion into the stool and sweat; with those of Malberti and Ravani (123) , who used a slightly higher dialysate Ca; and with those of Sigrist and McIntyre (121) , who also did not take into account losses from sweat and secretion of Ca into the stool. The ⌬ECF Ca , both with and without the addition of activated vitamin D, at levels of 50 mmol (2 g) Ca intake is not insubstantial.
Conclusions
This analysis, with the assumptions made, suggests that dialysis patients who consume Ͼ37.5 mmol (1.5 g) of elemental Ca have a positive ⌬ECF Ca that becomes numerically more positive when patients are given activated vitamin D. This Ca cannot stay in the ECF but must be deposited in either osseous or extraosseous sites or [Ca total ] would increase substantially. The extensive soft tissue calcification that is seen in many dialysis patients suggests that extraosseous sites may be the repository for this Ca (2,128 -135) . The quantity of Ca retained is not insignificant; 25 mmol/wk is approximately 1300 mmol/ yr, or approximately 4% of normal skeletal Ca (10,11).
Far more research needs to be done, however, to support or refute these conclusions. We clearly need an overall Ca balance study of dialysis patients using isotopic labeled Ca to measure fluxes between organs. We are administering Ca to bind intestinal phosphate yet do not even know how much is absorbed. Net Ca absorption should be measured at various levels of CKD, with and without activated vitamin D. We need to determine whether there are differences in human intestinal Ca absorption with the different activated vitamin D preparations. How does the anion administered with the Ca influence net Ca absorption? Can we influence where Ca is deposited-bone is often good, but soft tissues are always bad. What is the tradeoff between any reduction of increased circulating phosphate caused by additional dietary and, thus, absorbed Ca?
Our dialysis patients are dying from cardiovascular disease that is often associated with coronary calcification (2,128 -135 ). Ca that ideally should be sequestered in bone is being deposited in vessels. Although this maldistribution is almost certainly not simply due to Ca overload into the ECF Ca , there can be no vascular calcification without Ca to complex with phosphate. An increased ⌬ECF Ca will increase the driving force for mineralization of the unmineralized matrix in both bone and the collagen secreted by vascular smooth muscle cells that have been transformed into osteoblasts (23,24). It is incumbent on nephrologists who administer additional dietary Ca to patients in the form of phosphate binders to know how much of this Ca is absorbed, especially when patients receive concurrent activated vitamin D, and, after absorption, whether this Ca is deposited in osseous or extraosseous sites. Although on a daily basis nephrologists administer grams of elemental Ca to dialysis patients, the fate of this additional Ca is not known. It would be tragic if we were doing more harm than good. 
